Among them, MCL-1 inhibitors and BCL-2 antagonists such as ABT-737 and Navitoclax exhibit the strongest preclinical evidence for selectively inducing apoptosis in ATLL cells, particularly when combined with antiviral or kinase pathway inhibitors [55, 59]. The gene discussed is MCL1; the disease is adult T-cell leukemia/lymphoma.